Clinical value of perioperative levels of DNA and mRNA in plasma of patients with renal cell carcinoma

Salinas-Sánchez, Antonio S.; García‐Olmo, Dolores C.; Martínez-Sanchiz, C.; Picazo-Martínez, María G.; Giménez-Bachs, José M.; Flores-Bautista, Ana B.; Díaz-Piqueras, Ángela

doi:10.1016/j.tranon.2020.100999

Cited by 3 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure 1 , careful screening and verification identified eight studies that were eligible for meta-analysis. The main characteristics and details of these eligible studies Salinas-Sanchez et al (2021) , Lasseter et al (2020) , Yamamoto et al (2018) , Lu et al (2016) , Wan et al (2013) , De Martino et al (2012) , Ellinger et al (2012) , Hauser et al (2010) are summarized in Table 1 . These eight eligible studies featured a total of 754 patients, with a median sample size of 87 (range: 33–229, mean: 94).…”

Section: Resultsmentioning

confidence: 99%

“…Cf-DNA was primarily detected by next generation sequencing or PCR-based method, and it could be characterized by composition (size, fragment or integrity), concentration (total, panel or specified gene) or genetic characteristics (methylation or nucleotide variants) ( Table 1 ). Of these, three studies extracted DNA from serum Hauser et al (2010) , De Martino et al (2012) , Ellinger et al (2012) , while the other five studies extracted DNA from plasma ( Wan et al, 2013 ; Lu et al, 2016 ; Yamamoto et al, 2018 ; Lasseter et al, 2020 ; Salinas-Sanchez et al, 2021 ). The blood volume required for the detection of cf-DNA varied from 0.8 to 3 ml.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…A total of six eligible studies De Martino et al (2012) , Wan et al (2013) , Lu et al (2016) , Yamamoto et al (2018) , Lasseter et al (2020) , Salinas-Sanchez et al (2021) showed an association between cf-DNA and prognosis for patients with RCa. Two study investigated the association between cf-DNA expression and OS Lasseter et al (2020) , Salinas-Sanchez et al (2021) , while another study investigated the association between cf-DNA and DFS De Martino et al (2012) , these data could not be merged. As for the other three studies, one investigated the association between cf-DNA expression and PFS Yamamoto et al (2018) , while the other investigated the association between cf-DNA expression and RFS (recurrence free survival) ( Wan et al, 2013 ; Lu et al, 2016 ); these data could not be merged.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Meta-Analysis of the Diagnostic Value of Cell-free DNA for Renal Cancer

Jiang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cell-free DNA (cf-DNA) has been reported to represent a suitable material for liquid biopsy in the diagnosis and prognosis of various cancers. We performed a meta-analysis of published data to investigate the diagnostic value of cf-DNA for renal cancer (RCa). Systematic searches were conducted using Pubmed, Embase databases, Web of Science, Medline and Cochrane Library to identify relevant publications until the 31st March 2021. For all patients, we evaluated the true diagnostic value of cf-DNA by calculating the number of true positive, false positive, true negative, and false negative, diagnoses by extracting specificity and sensitivity data from the selected literature. In total, 8 studies, featuring 754 RCa patients, and 355 healthy controls, met our inclusion criteria. The overall diagnostic sensitivity and specificity for cf-DNA was 0.71 (95% confidence interval (CI), 0.55–0.83) and 0.79 (95% CI, 0.66–0.88), respectively. The pooled positive likelihood ratio and pooled negative likelihood ratio were 3.42 (95% CI, 2.04–5.72) and 0.36 (95% CI, 0.23–0.58), respectively. The area under the summary receiver operating characteristic curve was 0.82 (95% CI, 0.79–0.85), and the diagnostic odds ratio was 7.80 (95% CI, 4.40–13.85). Collectively, our data demonstrate that cf-DNA has high specificity and sensitivity for diagnosing RCa. Therefore, cf-DNA is a useful biomarker for the diagnosis of RCa.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Meta-Analysis of the Diagnostic Value of Cell-free DNA for Renal Cancer

Jiang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…In addition, cell-free nucleic acids have obvious potential for monitoring postoperative outcomes. Plasma GAPDH and hTERT cfDNA levels decreased significantly postoperatively and correlated with the risk of postoperative progression and death [ 191 ]. One study reported that each fg/mL of postoperative GAPDH cfDNA and hTERT cfDNA increased the risk of progression by 1.04 and 1.2 in Patients with RCC, respectively.…”

Section: Introductionmentioning

confidence: 99%

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application

Zheng

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is a major pathological type of kidney cancer and is one of the most common malignancies worldwide. The unremarkable symptoms of early stages, proneness to postoperative metastasis or recurrence, and low sensitivity to radiotherapy and chemotherapy pose a challenge for the diagnosis and treatment of RCC. Liquid biopsy is an emerging test that measures patient biomarkers, including circulating tumor cells, cell-free DNA/cell-free tumor DNA, cell-free RNA, exosomes, and tumor-derived metabolites and proteins. Owing to its non-invasiveness, liquid biopsy enables continuous and real-time collection of patient information for diagnosis, prognostic assessment, treatment monitoring, and response evaluation. Therefore, the selection of appropriate biomarkers for liquid biopsy is crucial for identifying high-risk patients, developing personalized therapeutic plans, and practicing precision medicine. In recent years, owing to the rapid development and iteration of extraction and analysis technologies, liquid biopsy has emerged as a low cost, high efficiency, and high accuracy clinical detection method. Here, we comprehensively review liquid biopsy components and their clinical applications over the past 5 years. Additionally, we discuss its limitations and predict its future prospects.

show abstract

The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples

Peng,

Pan,

Zhou

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cell-free DNA (cfDNA), a burgeoning class of molecular biomarkers, has been extensively studied across a variety of biomedical fields. As a key component of liquid biopsy, cfDNA testing is gaining prominence in disease detection and management due to the convenience of sample collection and the abundant wealth of genetic information it provides. However, the broader clinical application of cfDNA is currently impeded by a lack of standardization in the preanalytical procedures for cfDNA analysis. A number of fundamental challenges, including the selection of appropriate preanalytical procedures, prevention of short cfDNA fragment loss, and the validation of various cfDNA measurement methods, remain unaddressed. These existing hurdles lead to difficulties in comparing results and ensuring repeatability, thereby undermining the reliability of cfDNA analysis in clinical settings. This review discusses the crucial preanalytical factors that influence cfDNA analysis outcomes, including sample collection, transportation, temporary storage, processing, extraction, quality control, and long-term storage. The review provides clarification on achievable consensus and offers an analysis of the current issues with the goal of standardizing preanalytical procedures for cfDNA analysis.

show abstract

Clinical value of perioperative levels of DNA and mRNA in plasma of patients with renal cell carcinoma

Cited by 3 publications

References 24 publications

Meta-Analysis of the Diagnostic Value of Cell-free DNA for Renal Cancer

Meta-Analysis of the Diagnostic Value of Cell-free DNA for Renal Cancer

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application

The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples

Contact Info

Product

Resources

About